Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11524 posts found.

Pfizer and BMS’ blood thinner Eliquis approved in Europe

May 23, 2011 Sales and Marketing BMS, Eliquis, Pfizer, apixaban

Pfizer and Bristol-Myers Squibb’s eagerly anticipated blood thinner Eliquis has gained European approval. A twice-daily oral Factor Xa inhibitor, Eliquis …
News
medeconnect_nicola_miles

Nicola Miles joins MedeConnect

May 23, 2011 Sales and Marketing appointment, sales and marketing

MedeConnect Healthcare Insight, the market research division of Doctors.net.uk, has strengthened its senior research team with the appointment of Nicola …
Appointment

Shire promotional magnet attracts FDA wrath

May 20, 2011 Medical Communications, Sales and Marketing FDA, Shire

The use of a promotional magnet by marketers at Shire has attracted trouble from the FDA. The magnet, which is …
News

Pfizer’s cancer drug meets end points in head-to-head study

May 20, 2011 Research and Development, Sales and Marketing Pfizer, axitinib, rcc

Pfizer’s investigational cancer drug axitinib significantly increased survival in kidney cancer patients when compared to Bayer’s standard treatment Nexavar. New …
News
Takeda headquarters

Takeda buys Nycomed for $13.6bn

May 19, 2011 Manufacturing and Production, Research and Development, Sales and Marketing Nycomed, Takeda

Takeda has acquired Swiss specialist pharma firm Nycomed, boosting its presence in emerging markets. The deal comes in at 9.6 …
News

Grunenthal in talks to sell pain drug portfolio

May 19, 2011 Sales and Marketing Grunenthal, Stada, chronic pain, pain therapeutics

Grunenthal is negotiating a 360 million euro deal to sell Central and Eastern European rights to some of its pain …
News

Digital media – spreading the word on Return on Investment

May 19, 2011 Medical Communications, Sales and Marketing ROI, digital marketing

The rise of digital marketing in the pharma sector has brought renewed focus to tracking effectiveness, because digital is seen …
Feature
Merck & Co's Victrelis (boceprevir)

Merck and Roche sign hepatitis C co-promotion deal

May 18, 2011 Medical Communications, Sales and Marketing Merck, Roche, hepatitis C

Merck & Co and Roche have signed an agreement that will see them co-promote each other’s hepatitis C drugs in …
News

Pfizer files lung cancer drug in US and Japan

May 18, 2011 Sales and Marketing NSCLC, Pfizer, crizotinib

Pfizer has submitted its oral lung cancer drug crizotinib for regulatory approval in the US and Japan. Crizotinib is an …
News
Shire UK

Shire makes $750m regenerative medicines acquisition

May 18, 2011 Manufacturing and Production, Research and Development, Sales and Marketing Shire, regenerative medicine

Shire’s ambitions to build a regenerative medicine business will soon be realised following its $750 million acquisition of Advanced BioHealing. …
News

Teva plans Japan expansion with Taiyo buy

May 17, 2011 Sales and Marketing Taiyo, Teva, generics

Teva is to acquire a majority stake in Taiyo, Japan’s third largest generics company for $460 million in cash. The …
News

Shield Therapeutics appoints finance chief

May 16, 2011 Sales and Marketing appointment, sales and marketing

Swiss specialty pharma company Shield Therapeutics has appointed Richard Jones to the newly-created role of chief financial officer. He has …
Appointment
Merck & Co's Victrelis (boceprevir)

Merck’s hepatitis drug Victrelis approved by FDA

May 16, 2011 Sales and Marketing Merck & Co, Victrelis, boceprevir, hepatitis C

The FDA has approved Merck’s hepatitis C drug Victrelis, the first oral treatment for the disease. Victrelis (boceprevir) has been …
News
ABPI's London offices

ABPI and BIA move in together

May 16, 2011 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, BIA

The UK’s pharma industry association the ABPI and its biotech equivalent the BIA are jointly relocating to new London offices. …
News

Price concession helps change NICE’s mind on Simponi

May 13, 2011 Sales and Marketing NICE, Simponi, TNF, merck sharp and dohme

NICE has provisionally recommended Merck Sharp & Dohme’s Simponi for rheumatoid arthritis alongside other drugs in the TNF inhibitor class. …
News
The Gateway to Local Adoption Series

Latest content

Secarna appoints Jens Holstein and Richard Mark Engelhard to new Advisory Board

March 25, 2026

Roche adds 2,176 NVIDIA Blackwell GPUs to its hybrid-cloud AI factory

March 25, 2026

ReproNovo appoints Mark Altmeyer as Chairman of the Board

March 24, 2026

EndoCyclic New Drug application approved by US FDA for endometriosis treatment

March 24, 2026

Mestag Therapeutics appoints Lindsey Rolfe as Chief Medical Officer and Pascal Merchiers as Chief Development Officer

March 23, 2026